Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression

This double-blind, randomised, placebo-controlled trial (n=54) will assess the safety and efficacy of low-dose ketamine infusion as an add-on treatment for adolescents with treatment-resistant depression (TRD).

The study, sponsored by Taipei Veterans General Hospital, Taiwan, aims to enrol adolescents aged 13 to 19 with TRD, defined as poor response to at least two antidepressants. The trial will investigate whether 0.5 mg/kg ketamine infusion is a safe and effective treatment for reducing depressive symptoms and suicidal ideation. Previous studies have shown promising results with ketamine in adult TRD, but this will be the first clinical trial to explore its effects in adolescents.

Participants will be monitored for changes in depression severity, suicidal thoughts, and overall safety of the treatment. The study commenced in March 2022 and is expected to complete in December 2026.

Topic Depression Treatment-Resistant Depression
Compound Ketamine
Country Taiwan
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Taipei Veterans General Hospital
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.